ArticleMolecular neurobiology2025
Long Non-coding RNA CRNDE Promotes the Development of Glioma by Inducing Polarization of M2-Type Macrophages.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Macrophage-derived long non-coding RNAs in cancer: pioneering targets for immune modulation and personalized therapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma is the most common primary malignant brain tumor globally, with a poor prognosis due to its complex interaction with the tumor microenvironment (TME). Despite advancements in glioma treatments, patient survival remains low, highlighting the need for additional molecular investigations. Long non-coding RNA Colorectal Neoplasia Differentially Expressed (lncRNA-CRNDE) has been linked to tumorigenesis in various cancers, influencing tumor progression via the tumor microenvironment (TME). Its role in tumor-associated macrophages in gliomas is unclear. This study investigates whether lncRNA-CRNDE promotes glioma progression by modulating these macrophages. Using the TCGA database, we assessed lncRNA-CRNDE expression and its prognostic significance in glioma, and its association with the immune microenvironment. We collected 42 glioma samples of different grades from our institution. Using RT-qPCR, Western blotting, ELISA, and other cell biology techniques, we analyzed lncRNA-CRNDE's effects on glioma proliferation and invasion and validated its role in glioma progression through animal model experiments. TCGA bioinformatic analysis showed higher lncRNA-CRNDE expression in glioma than in normal tissues, which correlated with poorer prognosis. Clinical glioma samples via RT-qPCR also showed elevated lncRNA-CRNDE in tumors, which was associated with reduced survival. Cellular experiments confirmed lncRNA-CRNDE's promotion of glioma proliferation and invasion, which was associated with the tumor microenvironment (TME). Further studies revealed lncRNA-CRNDE's role in macrophage polarization in the TME, enhancing glioma progression. Animal experiments confirmed lncRNA-CRNDE's role in glioma progression. LncRNA-CRNDE is highly expressed in M2 macrophages and strongly associated with glioma progression. It is a potential prognostic marker and therapeutic target for glioma.
Indexed as
Identifiers
40320505What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.